M&A activity snapshot
Specialty chemicals M&A is running at lower volume but steady pricing. Capstone Partners counted 63 chemicals transactions through mid-2025, down 27.6% from 87 a year earlier. Even so, the average purchase multiple approached 9.0x EV/EBITDA, up from 8.4x in the prior-year period.
Value is concentrated in a few large deals. PwC measured $67 billion of chemicals deal value across 552 deals on a trailing twelve-month basis to Q1 2026, with eleven deals over $1 billion making up roughly 70%. Deloitte counted only 243 chemicals deals in the first half of 2025, the lowest half since before COVID.
Formulators sit in a narrow NAICS slot. Code 325998 covers miscellaneous chemical products and preparations, excluding basic chemicals, resins, paints and coatings, and cleaning compounds. Many specialty businesses buyers target, such as coatings or water-treatment producers, are classified elsewhere in subsector 325.
Who is buying
Private equity is the swing buyer. Sponsors made up 47.6% of chemicals deals through mid-2025, the highest share in Capstone's record, and platform acquisitions rose to 19.5% of deal volume. Capstone ties this to sticky customer relationships and the ability to pass through raw material costs.
Named sponsor deals show the pattern. Pritzker Private Capital agreed to acquire Buckman, a water-treatment and process chemicals company, and earlier acquired Americhem, a color masterbatch and additives maker. Windjammer Capital bought MFG Chemical, a Chattanooga formulator serving water treatment and industrial coatings, from Platte River Equity in January 2026.
Distributors and strategics buy formulation capability. Gemspring-backed Shrieve, a specialized chemicals distributor, acquired FIS Chemicals, an Aberdeen-based formulator and manufacturer, in April 2026. Strategic acquirers still accounted for 52.4% of chemicals transactions through mid-2025, increasingly targeting businesses in the $10-250 million range.
What buyers look for
Buyers want proof the business is specialty, not commodity in disguise. PwC says coatings, advanced materials, nutrition, water, and other defensible end markets still attract premium multiples when they bring technology, customer intimacy, or formulation know-how. End-market mix matters: ACC expects specialty chemicals tied to semiconductors, data centers, and healthcare to keep expanding.
The core KPIs are concrete:
- Gross margin stability through raw material swings, backed by pass-through clauses or a pricing record.
- Products specified into customer processes, where switching requires requalification, so revenue survives an ownership change.
- Formulation IP that is documented, owned by the company, and not held in one chemist's head.
- Customer and end-market mix, with no single account dominating volume.
Buyers also underwrite normalized earnings. PwC says deals with normalised earnings and a credible value creation plan should draw interest, while assets marketed on peak-cycle earnings may stall.
What makes a strong company
Regulatory readiness separates clean deals from slow ones. New molecules need EPA clearance: anyone making or importing a new chemical substance must file a pre-manufacture notice at least 90 days before manufacture. A buyer will check that every substance the company sells is on the TSCA Inventory or covered by an exemption.
PFAS is the live issue. EPA's TSCA section 8(a)(7) rule covers anyone who has manufactured or imported PFAS or PFAS-containing articles in any year since January 1, 2011. EPA has delayed the reporting window several times and proposed scope exemptions in November 2025, so buyers ask whether a target is in scope and has its records assembled.
Exporters face a second regime. EU REACH requires registration before a substance is manufactured or imported into the EU at one tonne or more per year. Strong sellers know whether they, an EU importer, or a customer holds each registration.
Site history is a standard diligence item. EPA recognizes ASTM E1527-21 as a way to conduct a Phase I environmental site assessment under its All Appropriate Inquiries rule. A recent, clean Phase I, with any findings already addressed, removes a common source of escrows and price cuts.
Valuation and deal structure
Specialty pricing runs well ahead of commodity. Capstone reports chemicals middle-market multiples averaged 10.0x EV/EBITDA from 2021 through mid-2025, versus 9.0x for broader Industrials. Excluding discounted divestitures, the mid-2025 average rose to 9.6x.
Commodity-linked assets sit lower. Gemspring agreed to buy Goodyear's synthetic rubber business, Goodyear Chemical, for $650 million, or about 5.0x EV/EBITDA. The Borealis-Borouge purchase of NOVA Chemicals, a polyolefins producer, was valued at about 7.5x through-the-cycle EBITDA.
Smaller formulators should not expect large-deal multiples. Chemicals-specific lower-middle-market data is not published by the sources reviewed here. As a cross-sector proxy, GF Data's lower-middle-market manufacturing deals averaged 5.8x TEV/EBITDA in H1 2025. Environmental findings are commonly handled through escrows, specific indemnities, or price adjustments; the sources above do not quantify how often.
Outlook
Expect a selective market through 2027. ACC forecasts U.S. specialty chemical output to slip 0.3% in 2026 as demand stays weak in several categories. Deloitte expects portfolio reevaluations could drive a wave of consolidation after 2026.
Carve-outs from large chemical companies and sponsor platforms will keep supplying deals. Formulators with documented IP, specified-in customers, clean sites, and settled TSCA and PFAS positions should draw interest even in a soft cycle.
Own a specialty chemicals business and want a market-data starting point? Run the valuation tool or see the broader manufacturing M&A picture. See also: how buyers build acquisition target lists.